Proxy Statement Form 8 K

Item 5.08Shareholder Director Nominations.

The Board of Directors (the "Board") of Conduit Pharmaceuticals Inc. (the "Company") previously established October 2, 2024 as the date for its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Board has determined it is in the best interests of the Company's stockholders to postpone the previously scheduled Annual Meeting.

The Board of the Company has now established December 18, 2024, as the date for the Annual Meeting. The Board also established October 25, 2024, as the record date for the Annual Meeting. Due to the fact that the Company did not hold an annual meeting of stockholders in 2023, the Company is providing the due date for submission of any qualified stockholder proposal or director nominations.

In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Company's bylaws (the "Bylaws"), the deadline for receipt of stockholder proposals or nominations for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than September 16, 2024. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Bylaws.